EUVIMED · CrossrefJournal
Expert Review of Pharmacoeconomics & Outcomes Research
ISSN 1473-7167 · Informa UK Limited
Latest articles
Cost-effectiveness analysis of sintilimab versus docetaxel as second-line therapy for squamous non-small cell lung cancer in China
Current and emerging measures and methods for evaluating medication adherence behaviors
Cost-effectiveness analysis of finotonlimab in combination with bevacizumab biosimilar SCT510 as first-line therapy for advanced hepatocellular carcinoma
Drug acquisition accounts for a minor share of the costs associated with dobutamine–milrinone escalation in cardiogenic shock: a propensity-weighted cost analysis from Indonesia
An expert-AI co-creation framework for robust health economic simulations
Cost-effectiveness analysis of dostarlimab plus chemotherapy versus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer
Unlocking herpes zoster vaccination value in Spain: return on investment and actuarial model
Affordability and relative economic burden of multiple sclerosis biologics in South America: a cross-country analysis of prices, purchasing power and regulatory access
Potential savings in Medicaid antiseizure medication reimbursement, 2008–2025: persistent brand-name reimbursement despite generic availability
National long-term trends in benzodiazepine outpatients prescription claims, Medicaid reimbursement, and average reimbursement per prescription in the United States, 2010–2024
Cost-effectiveness of neoadjuvant/adjuvant pembrolizumab versus standard of care for locally advanced head and neck squamous cell carcinoma in China and the United States
Nivolumab dose stewardship in routine oncology practice: a real-world health-economic simulation
The association between cardiovascular diseases and their risk factors in Austria and Slovakia: regression analyses based on the European Health Interview Survey (2019)
Resource utilization and costs of managing severe adverse events associated with chemotherapy and immunotherapy in lung cancer: a consensus-based microcosting study in Jordan
COVID-19 and pharmaceutical sales in Karaman, Turkey (2019–2021): a hierarchical ATC analysis
Health-related quality of life in adult patients with moyamoya disease in Japan: a single-center study
Medication adherence in clinical trials: measurement methods, methodological challenges, and reporting standards
A comprehensive assessment of cholinesterase inhibitors for the treatment of Alzheimer’s disease based on drug selection recommendations for Chinese medical institutions
The economic impact of opportunistic PSA screening: a real-world cost analysis from China amid evolving policy landscape
Treatment patterns and outcomes in proximal humerus fracture management: a claims-based retrospective analysis of real-world US patient data
Cost-effectiveness analysis comparison of etelcalcetide, paricalcitol, and cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease
Impact of the Inflation Reduction Act on Medicare MTM eligibility among beneficiaries with diabetes: evidence from 2022–2023
Institutional and national budget impact of alternative pembrolizumab dosing in non-small cell lung cancer: a real-world pharmacoeconomic analysis
Cost-neutral adoption of anti-VEGF therapies in neovascular age-related macular degeneration
Determinants of out-of-pocket health expenditure: cross-country evidence across World Bank income groups
Patient and public perspectives on artificial intelligence in healthcare and health research: comfort, perceived utility, and concern
Cost-effectiveness analysis of liposomal irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas in Greece
Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China
Resmetirom for noncirrhotic metabolic dysfunction–associated steatohepatitis with liver fibrosis: establishing a value-based price in China, the UK, France, and Germany
Protecting the patient in value-based pricing schemes
EUVIMED